BriaCell Therapeutics Corp. (BCTX) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is bullish — 1 Buy.
Analysts estimate Earnings Per Share (EPS) of $-3.01 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2025: actual $-86.25 vs est $-3.01 (missed -2765.4%). Analyst accuracy: 3%.
BCTX Analyst Ratings
Buy
Based on 1 analysts giving stock ratings to BriaCell Therapeutics Corp. in the past 3 months
EPS Estimates — BCTX
3%
Analyst Accuracy
Inaccurate
1 year compared
Actual vs Estimate
2025
Actual –$86.25
vs Est –$3.01
▼ 96.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — BCTX
Revenue Trend
Analysts expect stable revenue going forward.
